Zobrazeno 1 - 10
of 240
pro vyhledávání: ''
Autor:
Nilay Shah, Xiaoxi Yao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie Payne, Andrew H. Limper
Publikováno v:
Annals of the American Thoracic Society. 18:1121-1128
Rationale: In October 2014, the antifibrotic medications pirfenidone and nintedanib became the first medications approved by the U.S. Food and Drug Administration for use in patients with idiopathi...
Autor:
Antoinette Moran, Felix Ratjen, Daniel Gelfond, Jill M. VanDalfsen, Sonya L. Heltshe, John P. Clancy, Umer Khan, Scott H. Donaldson, Steven M. Rowe, Scott D. Sagel, Drucy Borowitz
Publikováno v:
Annals of the American Thoracic Society. 18:75-83
Rationale: The combination of lumacaftor (LUM) and ivacaftor (IVA) is an approved CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator treatment for homozygous F508del patients...
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:92-94
Autor:
Peter Lange, Mark T. Dransfield, Dave Singh, Sally Lettis, Robert A. Wise, David A. Lomas, David M.G. Halpin, Sally Kilbride, Neil R.W. Martin, Gerard J. Criner, C. Elaine Jones, David A. Lipson, Fernando J. Martinez, MeiLan K. Han
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Han, M K, Criner, G J, Dransfield, M T, Halpin, D M G, Jones, C E, Kilbride, S, Lange, P, Lettis, S, Lipson, D A, Lomas, D A, Martin, N, Wise, R A, Singh, D & Martinez, F J 2020, ' The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study A Randomized, Double-Blind, Multicenter Clinical Trial ', American Journal of Respiratory and Critical Care Medicine, vol. 202, no. 9, pp. 1237-1243 . https://doi.org/10.1164/rccm.201912-2478OC
Han, M K, Criner, G J, Dransfield, M T, Halpin, D M G, Jones, C E, Kilbride, S, Lange, P, Lettis, S, Lipson, D A, Lomas, D A, Martin, N, Wise, R A, Singh, D & Martinez, F J 2020, ' The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study A Randomized, Double-Blind, Multicenter Clinical Trial ', American Journal of Respiratory and Critical Care Medicine, vol. 202, no. 9, pp. 1237-1243 . https://doi.org/10.1164/rccm.201912-2478OC
Rationale: In the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients wit
Autor:
Qiang Li, Naomi E Hammond, David Shi Hao Liu, Carel J. Pretorius, Louise M Burrell, Jacobus P.J. Ungerer, Balasubramanian Venkatesh, Morag J. Young, Sandra L. Peake, David M. Evans, John Myburgh, Simon Finfer, Andrew Rhodes, Jeremy Cohen, John P. R. Moore, Laurent Billot, Brett McWhinney, Manoj Saxena, Rinaldo Bellomo, Dorrilyn Rajbhandari, Colin McArthur
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 202:700-707
Rationale: Whether biomarkers can identify subgroups of patients with septic shock with differential treatment responses to hydrocortisone is unknown.Objectives: To determine if there is heterogene...
Autor:
Keisuke Tsukioka, Masaaki Arakawa, Takashi Hasegawa, Hiroyuki Takeuchi, Akira Saito, Satoshi Watanabe, Hiroshi Ueno, Yosuke Kimura, Masachika Hayashi, Toshiyuki Koya, Toshiaki Kikuchi
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology. 63:57-66
It is well known that the prevalence of asthma is higher in athletes, including Olympic athletes, than in the general population. In this study, we analyzed the mechanism of exercise-induced bronchoconstriction by using animal models of athlete asthm
Autor:
Keiko Wakahara, Chihiro Mitsui, Kentaro Watai, Naozumi Hashimoto, Keiichi Kajiwara, Yuto Hamada, Yuma Fukutomi, Yosuke Kamide, Masami Taniguchi, Kiyoshi Sekiya, Yoshinori Hasegawa, Takahiro Tsuburai, Yuto Nakamura, Kenji Izuhara, Hiroaki Hayashi, Yasuhiro Tomita
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 201:1488-1498
Rationale: Aspirin-exacerbated respiratory disease is characterized by severe asthma, nonsteroidal antiinflammatory drug hypersensitivity, nasal polyposis, and leukotriene overproduction. Systemic ...
Autor:
Ashley C. Collins, Oksana A. Shlobin, Steven D. Nathan, Christopher S. King, G. Sese, Kareem Ahmad, M. Lemma Woldehanna, Anne Brown
Publikováno v:
TP48. TP048 COVID: ARDS CLINICAL STUDIES.
Rationale:The outbreak of COVID-19 in March of 2020 led to the emergent search for treatment options. Passive immune therapy with COVID-19 convalescent plasma (CCP) therapy was utilized as an investigational therapy. We designed an open label study a
Publikováno v:
TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS.
Introduction: Invasive pulmonary aspergillosis (IPA) is a rare, severe fungal infection with a poor prognosis and high mortality rate. IPA is mainly noted in patients with immunosuppressed status, hematological malignancies and stem cell transplants.
Publikováno v:
TP49. TP049 COVID: ARDS AND ICU MANAGEMENT.
Rationale: We aim to describe the clinical characteristics and outcomes of patients who received Tocilizumab for COVID-19 pneumonia at our institution between March 20 and October 26, 2020. Methods: In this single center, retrospective, observational